JP2007530582A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530582A5
JP2007530582A5 JP2007505199A JP2007505199A JP2007530582A5 JP 2007530582 A5 JP2007530582 A5 JP 2007530582A5 JP 2007505199 A JP2007505199 A JP 2007505199A JP 2007505199 A JP2007505199 A JP 2007505199A JP 2007530582 A5 JP2007530582 A5 JP 2007530582A5
Authority
JP
Japan
Prior art keywords
substituted
compound
group
aryl
cycloheteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/009909 external-priority patent/WO2005097760A1/en
Publication of JP2007530582A publication Critical patent/JP2007530582A/ja
Publication of JP2007530582A5 publication Critical patent/JP2007530582A5/ja
Pending legal-status Critical Current

Links

JP2007505199A 2004-03-26 2005-03-25 代謝可能部分を含む複素環抗ウイルス化合物およびその使用 Pending JP2007530582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55662504P 2004-03-26 2004-03-26
US58290304P 2004-06-24 2004-06-24
PCT/US2005/009909 WO2005097760A1 (en) 2004-03-26 2005-03-25 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses

Publications (2)

Publication Number Publication Date
JP2007530582A JP2007530582A (ja) 2007-11-01
JP2007530582A5 true JP2007530582A5 (https=) 2008-05-01

Family

ID=34963905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505199A Pending JP2007530582A (ja) 2004-03-26 2005-03-25 代謝可能部分を含む複素環抗ウイルス化合物およびその使用

Country Status (4)

Country Link
US (1) US20050239751A1 (https=)
EP (1) EP1740556A1 (https=)
JP (1) JP2007530582A (https=)
WO (1) WO2005097760A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
CA2606106A1 (en) * 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
PT2178858E (pt) 2007-08-02 2012-02-24 Recordati Ireland Ltd Novos compostos heterocíclicos como antagonistas de mglu5
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011009484A1 (en) * 2009-07-22 2011-01-27 Novartis Ag Arylpyrazoles and arylisoxazoles and their use as pkd modulators
US20130210836A1 (en) 2010-07-19 2013-08-15 Syngenta Crop Protection Llc Microbicides
EP2595985A1 (en) 2010-07-19 2013-05-29 Syngenta Participations AG Isoxazole, isothiazole, furane and thiophene compounds as microbicides
WO2013007550A1 (en) 2011-07-08 2013-01-17 Syngenta Participations Ag Fungicide mixtures
WO2013011010A1 (en) 2011-07-19 2013-01-24 Syngenta Participations Ag Fungizide mixtures
WO2014027696A1 (ja) 2012-08-17 2014-02-20 中外製薬株式会社 抗hcv作用を有する経口投与可能なビリジオファンジン誘導体
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
CN103145688A (zh) * 2013-04-02 2013-06-12 黄冈鲁班药业有限公司 4,5-二氯甲基-1,3-二氧杂环戊烯-2-酮的制备方法
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10703712B2 (en) 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
JP7258763B2 (ja) 2017-03-15 2023-04-17 メタクリン,インク. ファルネソイドx受容体アゴニストおよびその使用
CA3055990A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
AU2019344903B2 (en) 2018-09-18 2025-02-27 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
KR20220155356A (ko) 2020-03-18 2022-11-22 메타크린, 인크. 파르네소이드 x 수용체 효능제의 결정형

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852503A (en) * 1953-12-31 1958-09-16 American Cyanamid Co 2, 5-bis (p-aminophenyl) furan azo derivatives
NL217825A (https=) * 1956-06-04
BE581861A (https=) * 1958-08-20
US3335149A (en) * 1963-08-21 1967-08-08 Monsanto Co Thiazole diamines
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
US3964896A (en) * 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
US3853893A (en) * 1973-04-02 1974-12-10 Squibb & Sons Inc Anthelmintic 5-(pyridyl)-3-(isothiocyanophenyl) oxadiazoles
DE2659709C3 (de) * 1976-12-31 1982-05-06 Hoechst Ag, 6000 Frankfurt 2,5-Bis-(4-aminophenyl)-1,3,4-oxadiazole und ihre Verwendung
DE3514182A1 (de) * 1985-04-19 1986-10-23 Basf Ag, 6700 Ludwigshafen Elektrophotographisches aufzeichnungsmaterial
DE3623302A1 (de) * 1985-11-09 1987-05-14 Bayer Ag Nicotinsaeurederivate
US4777258A (en) * 1987-04-23 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Method for preparing 2,5-dipcryl-1,3,4-oxadiazole
DE4016049A1 (de) * 1990-05-18 1991-11-21 Basf Ag 3-isoxazolylbenzylester, ihre herstellung und ihre verwendung
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4137940A1 (de) * 1991-11-18 1993-05-19 Basf Ag 3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
DE4408084A1 (de) * 1994-03-10 1995-09-14 Hoechst Ag 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020035156A1 (en) * 1997-04-18 2002-03-21 Barbara Roniker Combination therapy in the prevention of cardiovascular disorders
CA2307613A1 (en) * 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonist as a prophylactic and therapeutic agent for nephritis
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
HRP20050168A2 (en) * 2002-08-23 2005-10-31 Rigel Pharmaceuticals Pyridyl substituted heterocycles useful for treating or preventing hcv infection
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
WO2004099164A1 (en) * 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
US7220745B2 (en) * 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV

Similar Documents

Publication Publication Date Title
JP2007530582A5 (https=)
AU2009268469B2 (en) Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway
JP2001526222A5 (https=)
JP2024007504A5 (https=)
JP2002543185A5 (https=)
JP2018520195A5 (https=)
JP2009543867A5 (https=)
JPWO2023018809A5 (https=)
JP2019517509A (ja) ヒストンデアセチラーゼインヒビターを含む組合せ
JP2018511631A5 (https=)
JP2010501639A (ja) 炎症性疾患の新規治療方法
JP2012515787A5 (https=)
JP2012512886A5 (https=)
KR920009796A (ko) 3-아미도인돌릴 유도체
JP2005518357A5 (https=)
JP2012530765A5 (https=)
JP2010516701A5 (https=)
JP2010516700A5 (https=)
JP2013511526A5 (https=)
CA2265746C (en) Agent for inhibition of cytokine production and agent for inhibition of cell adhesion
EP4440575A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
BR112016019161B1 (pt) Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
JP2019513812A5 (https=)
JP2007510671A5 (https=)
JP5862897B2 (ja) 腎機能障害の予防又は治療に用いる医薬